Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low‐density lipoprotein‐cholesterol (LDL‐C) by decreasing the expression of the LDL‐receptor on hepatic cells. Ongericimab (JS002) is a novel PCSK9 monoclonal antibody that exhibits a long‐acting LDL‐C lowering effect by...

Descrición completa

Detalles Bibliográficos

Principais autores:	Juanjuan Jiang, Li Xu, Lin Chai, Xiaoyuan Guan, Li Zhang, Hong Liu, Yan Yan, Lili Li, Yi Zhao, Xuelian Bai, Lei Tian, Youhong Jia
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2024-11-01
Series:	Clinical and Translational Science
Acceso en liña:	https://doi.org/10.1111/cts.70061
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!